Drugs / JK-1201I
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04366648 | May 2018 → Mar 2021 | cancer | JenKem Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06586866 | Sep 2024 → May 2026 overdue | metastatic malignant neoplasm in the brain, triple-negative breast carcinoma | JenKem Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06595186 | Oct 2022 → Aug 2026 overdue | glioblastoma | JenKem Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06581380 | Sep 2024 → Nov 2027 expected | small cell lung carcinoma | JenKem Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05158491 Comparator | Nov 2021 → Dec 2022 | small cell lung carcinoma | JenKem Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JK-1201I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04366648 ↗ |
| Known as | PEG-Irinotecan | “Injectable PEG-Irinotecan (JK-1201I)” NCT04366648 ↗ |
| Route | Intravenous | “JK-1201I will be administered as an IV infusion” NCT06581380 ↗ |